The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Korneeva I.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Novikova E.G.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena

Sergeeva N.S.

Russian University of Peoples' Friendship

Alentov I.I.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Evolution of a view on the marker recurrence of ovarian cancer

Authors:

Korneeva I.A., Novikova E.G., Sergeeva N.S., Alentov I.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(4): 73‑80

Read: 12306 times

Download PDF (RU)
Contact the author
Table of contents

EVOLUTION OF A VIEW ON THE MARKER RECURRENCE OF OVARIAN CANCER
EVOLUTION OF A VIEW ON THE MARKER RECURRENCE OF OVARIAN CANCER

To cite this article:

Korneeva IA, Novikova EG, Sergeeva NS, Alentov II. Evolution of a view on the marker recurrence of ovarian cancer. P.A. Herzen Journal of Oncology. 2013;2(4):73‑80. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Abstract:

The review illustrates the evolution of views on the problem of marker recurrences of ovarian cancer. It discusses the sphere of application of the marker CA125 in ovarian cancer. It analyzes the results of the MRC/OV05-EORTC 55955 international multicenter randomized trial and gives arguments for and against the expediency of using regular CA125 tests for the early detection of a recurrence.

Keywords:

marker recurrence
ovarian cancer
CA125
MRC/OV05-EORTC 55955

Authors:

Korneeva I.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Novikova E.G.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena

Sergeeva N.S.

Russian University of Peoples' Friendship

Alentov I.I.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Close metadata

References:

  1. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 1975; 42: 101-4.
  2. Bristow R.E., Tomacruz R.S., Armstrong D.K. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 2002; 20: 1248-59.
  3. Chi D.S., Vencatraman E.S., Masson V., Hoskins W.J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol. Oncol. 2000; 77: 227-31.
  4. Order S.E., Donahue V.C., Knapp R.C. Immunotherapy of ovarian carcinoma: An experimental model. Cancer. 1973; 32 (3): 573-9.
  5. Bast R.C. Jr., Berek J.S., Obrist R. et al. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res. 1983; 43 (3): 1395-401.
  6. Bast R.C. Jr., Feeney M., Lazarus H. et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 1981; 68 (5): 1331-7.
  7. Bast R.C. Jr., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H. et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 1983; 309 (15): 883-7.
  8. Alagoz T., Buller R.E., Eeiman M. et al. What is a normal CA125 level? Gynecol. Oncol. 1994; 53: 93-7.
  9. Jacobs I., Davies A.P., Bridges J. et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br. Med. J. 1993; 306: 1030-4.
  10. Jacobs U., Skates S.J., MacDonald N. et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353: 1207-10.
  11. Buller R.E., Berman M.L., Bloss J.D. et al. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol. Oncol. 1992; 47 (1): 87-92.
  12. Nagele F., Petru E., Medl M. et al. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet. Gynecol. 1995; 86: 259-64.
  13. Riedinger J.M. Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study. Bull. Cancer. 2007; 94: 287-95.
  14. Juretzka M.M., Barakat R.R., Chi D.S. et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol. Oncol. 2007; 104: 176-80.
  15. Akhmedova S.A. Sovershenstvovanie kliniko-laboratornoi kontseptsii ispol'zovaniya SA125 u bol'nykh rakom yaichnikov: Dis. ... kand. med. nauk. M.; 2003.
  16. Sergeeva N.S., Marshutina N.V. Serologicheskie opukholevye markery i ikh primenenie v onkologii. V kn.: Izbrannye lektsii po klinicheskoi onkologii. M.; 2000: 108-25.
  17. Rustin G.J., Kelloff G.J., Bast R.C., Barett J.K. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res. 2004; 10 (11): 3919-26.
  18. Rustin G.J., van der Burg M., Griffin C.L. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomized trial. Lancet. 2010; 376: 1155-63.
  19. 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. 2009; 27 (15, Suppl.): abstr. 5522.
  20. Bouchard D., Morisset D., Bourbonnais Y., Tremblay G.M. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 2006; 7 (2): 167-74.
  21. Kirchhoff C. Molecular characterization of epididymal proteins. Rev. Reprod. 1998; 3 (2): 86-95.
  22. Drapkin R., von Horsten H.H., Lin Y. et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65: 2162-9.
  23. MagginoT., Gadducci A., D'Addario V. et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol. 1994; 54: 117-23.
  24. Hough C.D., Sherman-Baust C.A., Pizer E.S. et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000; 60: 6281-7.
  25. Moore R.G., Brown A.K., Miller M.C. et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 2008; 108: 402-8.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.